Age-related macular degeneration.

Area of Science:

• Ophthalmology
• Genetics
• Pathogenesis of Age-Related Macular Degeneration

Background:

• Age-related macular degeneration (AMD) is a primary cause of irreversible vision impairment and blindness.
• AMD is classified into early (drusen, pigmentary changes) and late (neovascular, atrophic) stages.
• Pathogenesis involves multifactorial pathways including complement, lipid, angiogenic, and inflammatory processes, influenced by genetics (CFH, ARMS2) and lifestyle (smoking, diet).

Purpose of the Study:

• To review the current understanding of age-related macular degeneration (AMD) pathogenesis and treatment.
• To highlight advancements in managing neovascular AMD and the challenges in treating atrophic AMD.
• To discuss future directions in AMD research, including prevention, personalized medicine, and regenerative therapies.

Main Methods:

• Review of current literature on AMD pathogenesis, risk factors, and therapeutic interventions.
• Analysis of genetic and non-genetic factors contributing to AMD development and progression.
• Evaluation of the efficacy of existing treatments like anti-vascular endothelial growth factor (anti-VEGF) therapy and ongoing clinical trials.

Main Results:

• Genetic factors (CFH, ARMS2) and environmental factors (smoking, low antioxidant intake) significantly contribute to AMD risk.
• Nutritional supplements (zinc, antioxidants) can slow AMD progression.
• Intravitreal anti-VEGF therapies have significantly reduced vision loss from neovascular AMD.

Conclusions:

• Neovascular AMD is effectively treated with anti-VEGF agents, drastically reducing visual impairment.
• Atrophic AMD currently lacks proven treatments, representing a critical unmet need.
• Future AMD management will likely involve enhanced prevention, personalized medicine, novel therapeutics, and regenerative approaches.